IMR Press / FBL / Volume 23 / Issue 2 / DOI: 10.2741/4596

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma

Show Less
1 Department of General Surgery, Shanghai First People’s Hospital, Nanjing Medical University, Nanjing, China
2 Department of General Surgery, Wuxi Third People’s Hospital, Wuxi, China
Front. Biosci. (Landmark Ed) 2018, 23(2), 388–396; https://doi.org/10.2741/4596
Published: 1 January 2018
(This article belongs to the Special Issue MicroRNA in hepatic fibrosis and cirrhosis)
Abstract

Available evidence suggests that autophagy may serve as a tumor suppressor in cases of chronic liver disease and liver cirrhosis and that autophagic deficiency may lead to hepatocellular carcinoma (HCC). Recent studies suggested that the development of several tumor types could be regulated by microRNA-181a. However, the role of miR-181a in the autophagy of HCC remains unclear. In this study, we aimed to investigate the role of miR-181a in the autophagy of HCC. We found that the mRNA expression of miR-181a is higher but the level of autophagy is lower in human HCC compared to normal liver tissue. A luciferase assay confirmed that Atg5 is the target gene of miR-181a. Moreover, the results showed that an miR-181a sponge increased apoptosis in HepG2 cells and reduced the growth of tumors in a HepG2 cell xenograft tumor model. In conclusion, these results suggest that miR-181a can inhibit autophagy in HCC by targeting Atg5, resulting in decreased apoptosis of HCC cells and increased tumor growth.

Keywords
MicroRNA-181a
Autophagy
Atg5
Hepatocellular carcinoma
Share
Back to top